Privo Technologies Launches Promising Clinical Trial Across U.S.
Privo Technologies, Inc., a pioneering biopharmaceutical company specializing in nanotechnology-based cancer therapies, is excited to announce the activation of several top clinical sites in the U.S. for its ongoing CLN-004 trial. This study, which is currently in Phase 2/3, is designed to evaluate the safety and efficacy of two key assets—PRV111 and PRV211—in patients suffering from head and neck squamous cell carcinoma (HNSCC).
The trial aims to recruit participants from esteemed institutions renowned for their expertise in oncology.
Clinical Sites Actively Recruiting Participants
Among the leading institutions involved in this significant trial are:
- University of Chicago Medicine in Chicago.
- City of Hope located in Los Angeles.
- Miami Cancer Institute in Miami.
- Cleveland Clinic in Cleveland.
With this expansion, additional cancer centers are being activated and further announcements will follow shortly.
Expert Collaboration and Support
Dr. Manijeh Goldberg, the CEO of Privo Technologies, expressed her enthusiasm about the collaboration with leading head and neck oncology experts at these prestigious institutions. She stated, "Their participation in this trial highlights the significant potential of our innovative therapies to change the treatment landscape for patients struggling with HNSCC." This collaboration emphasizes the importance of multidisciplinary approaches in tackling complex cancer treatments.
Understanding the CLN-004 Trial Structure
The CLN-004 trial is organized into two distinct arms, each focusing on different methodologies for treating HNSCC.
- Arm 1: This component evaluates PRV111, a self-adhesive patch engineered for topical delivery of cisplatin directly to the tumor site. It targets patients diagnosed with carcinoma in situ (CIS) and high-grade dysplasia in the oral cavity. The intention is to enhance local control while potentially minimizing the need for invasive surgical procedures.
- Arm 2: The trial also assesses PRV211, an intraoperative chemotherapy system applied during surgery to the resected tumor bed. This aims to eliminate any residual microscopic disease, reducing the risk of tumor recurrence in patients across various HNSCC stages.
Both therapies are part of Privo's innovative PRV™ platform, which leverages nanotechnology to optimize localized delivery of chemotherapy agents, ensuring maximal therapeutic benefits while minimizing systemic side effects.
About Privo Technologies
Privo Technologies is dedicated to the development of revolutionary therapies that address significant unmet needs in cancer treatment, particularly concerning mucosal cancers. Utilizing its proprietary PRV™ platform, Privo focuses on enhancing patient outcomes through targeted and efficient drug delivery systems designed for precision and effectiveness.
Frequently Asked Questions
What is the primary goal of the CLN-004 trial?
The primary goal of the CLN-004 trial is to evaluate the safety and efficacy of PRV111 and PRV211 in patients with head and neck squamous cell carcinoma.
Where are the clinical sites located?
The trial is recruiting participants at notable institutions such as the University of Chicago Medicine, City of Hope, Miami Cancer Institute, and Cleveland Clinic.
Who leads the CLN-004 trial?
The CLN-004 trial is led by Privo Technologies, Inc., with Dr. Manijeh Goldberg as the CEO overseeing the initiative.
What are the two main arms of the trial?
Arm 1 evaluates PRV111 for topical delivery of cisplatin, while Arm 2 assesses PRV211 for intraoperative chemotherapy delivery.
How can individuals participate in the trial?
Individuals interested in participating in the CLN-004 trial can contact Privo Technologies directly for more information on eligibility and enrollment.
